Terms: = Ovarian cancer AND KMT2A, TRX1, 4297, MLL, ENSG00000118058, MLL/GAS7, HTRX1, HRX, ALL-1, MLL1A, CXXC7
34 results:
1. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
[No Abstract] [Full Text] [Related]
2. Therapy-related acute myeloid leukemia with
Yang X; Liu Q; Zhang R; Yang X; Wang L; Zhang Z; Li Y; Lin L
Indian J Pathol Microbiol; 2023; 66(4):865-867. PubMed ID: 38084551
[TBL] [Abstract] [Full Text] [Related]
3. Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3.
Li J; Chen Z; Xiao W; Liang H; Liu Y; Hao W; Zhang Y; Wei F
J Cell Mol Med; 2023 Nov; 27(21):3259-3270. PubMed ID: 37525498
[TBL] [Abstract] [Full Text] [Related]
4. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
5. Glycoproteome remodeling in mll-rearranged B-cell precursor acute lymphoblastic leukemia.
Oliveira T; Zhang M; Joo EJ; Abdel-Azim H; Chen CW; Yang L; Chou CH; Qin X; Chen J; Alagesan K; Almeida A; Jacob F; Packer NH; von Itzstein M; Heisterkamp N; Kolarich D
Theranostics; 2021; 11(19):9519-9537. PubMed ID: 34646384
[TBL] [Abstract] [Full Text] [Related]
6. Menin‑mll inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
Kato I; Kasukabe T; Kumakura S
Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
[TBL] [Abstract] [Full Text] [Related]
7. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C; Portwood SM; Przespolewski A; Wang ES
Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
[TBL] [Abstract] [Full Text] [Related]
8. The Anti-Proliferative Effect of Flavonoid Nanoparticles on the Human ovarian cancer Cell Line SK0V3.
Zhang C; Li X; Jin S; Zhang H; Wang R; Pei L; Zheng J
J Nanosci Nanotechnol; 2020 Oct; 20(10):6040-6046. PubMed ID: 32384950
[TBL] [Abstract] [Full Text] [Related]
9. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract] [Full Text] [Related]
10. Epigenetic synthetic lethality approaches in cancer therapy.
Yang H; Cui W; Wang L
Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
[TBL] [Abstract] [Full Text] [Related]
11. [
Guo T; Dong X; Shi G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):551-555. PubMed ID: 30378308
[TBL] [Abstract] [Full Text] [Related]
12. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract] [Full Text] [Related]
13. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos C; Selkirk CGH; Saya S; Bancroft E; Vertosick E; Dadaev T; Brendler C; Page E; Dias A; Evans DG; Rothwell J; Maehle L; Axcrona K; Richardson K; Eccles D; Jensen T; Osther PJ; van Asperen CJ; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Hart R; Glover W; Lam J; Taylor L; Salinas M; Feliubadaló L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Cook J; Rosario DJ; Buys SS; Conner T; Domchek S; Powers J; Ausems MG; Teixeira MR; Maia S; Izatt L; Schmutzler R; Rhiem K; Foulkes WD; Boshari T; Davidson R; Ruijs M; Helderman-van den Enden AT; Andrews L; Walker L; Snape K; Henderson A; Jobson I; Lindeman GJ; Liljegren A; Harris M; Adank MA; Kirk J; Taylor A; Susman R; Chen-Shtoyerman R; Pachter N; Spigelman A; Side L; Zgajnar J; Mora J; Brewer C; Gadea N; Brady AF; Gallagher D; van Os T; Donaldson A; Stefansdottir V; Barwell J; James PA; Murphy D; Friedman E; Nicolai N; Greenhalgh L; Obeid E; Murthy V; Copakova L; McGrath J; Teo SH; Strom S; Kast K; Leongamornlert DA; Chamberlain A; Pope J; Newlin AC; Aaronson N; Ardern-Jones A; Bangma C; Castro E; Dearnaley D; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lubinski J; Grindedal EM; McKinley J; Shackleton K; Mitra AV; Moynihan C; Rennert G; Suri M; Tricker K; ; Moss S; Kote-Jarai Z; Vickers A; Lilja H; Helfand BT; Eeles RA
Br J Cancer; 2018 Jan; 118(2):266-276. PubMed ID: 29301143
[TBL] [Abstract] [Full Text] [Related]
14. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.
Chen J; Solomides C; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2017 Feb; 79(2):369-380. PubMed ID: 28120035
[TBL] [Abstract] [Full Text] [Related]
15. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract] [Full Text] [Related]
16. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (trx1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
[TBL] [Abstract] [Full Text] [Related]
17. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
[TBL] [Abstract] [Full Text] [Related]
18. Bilateral ovarian B-lineage lymphoblastic lymphoma with mll gene rearrangement: a novel case in infancy.
Larish AM; Dolan M; Casey T; Perkins JL
J Pediatr Hematol Oncol; 2015 May; 37(4):e215-7. PubMed ID: 25493458
[TBL] [Abstract] [Full Text] [Related]
19. Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells.
Wang J; Yang H; Li W; Xu H; Yang X; Gan L
Biochim Biophys Acta; 2015 Mar; 1852(3):395-405. PubMed ID: 25483711
[TBL] [Abstract] [Full Text] [Related]
20. Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses.
Park BJ; Cha MK; Kim IH
Biomarkers; 2014 Nov; 19(7):604-10. PubMed ID: 25174623
[TBL] [Abstract] [Full Text] [Related]
[Next]
